MX2021010577A - Compuestos de union a pd-l1 multivalentes para tratar cancer. - Google Patents
Compuestos de union a pd-l1 multivalentes para tratar cancer.Info
- Publication number
- MX2021010577A MX2021010577A MX2021010577A MX2021010577A MX2021010577A MX 2021010577 A MX2021010577 A MX 2021010577A MX 2021010577 A MX2021010577 A MX 2021010577A MX 2021010577 A MX2021010577 A MX 2021010577A MX 2021010577 A MX2021010577 A MX 2021010577A
- Authority
- MX
- Mexico
- Prior art keywords
- multivalent
- binding compounds
- materials
- treating cancer
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Esta invención proporciona métodos y materiales para tratar el cáncer. La invención abarca métodos y materiales para administrar compuestos de unión a ligando de muerte programada 1 (PD-L1) y/o composiciones que contienen uno o más compuestos de unión a ligando de muerte programada 1 (PD-L1) monovalentes o multivalentes que se administran a un mamífero que tiene cáncer para tratar al mamífero. En algunos casos, un compuesto de unión a PD-L1 multivalente puede incluir dos o más polipéptidos de proteína de muerte celular programada 1 (PD-1) (y/o fragmentos de los mismos que tengan la capacidad de unirse a PD-L1). Esta invención también proporciona métodos y materiales para fabricar compuestos de unión a PD-L1 multivalentes y métodos y materiales para fabricar moléculas de ácido nucleico que codifiquen para compuestos de unión a PD-L1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962839916P | 2019-04-29 | 2019-04-29 | |
PCT/US2020/030240 WO2020223217A1 (en) | 2019-04-29 | 2020-04-28 | Multivalent pd-l1 binding compounds for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021010577A true MX2021010577A (es) | 2021-10-13 |
Family
ID=70779882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021010577A MX2021010577A (es) | 2019-04-29 | 2020-04-28 | Compuestos de union a pd-l1 multivalentes para tratar cancer. |
Country Status (13)
Country | Link |
---|---|
US (1) | US11485767B2 (es) |
EP (1) | EP3911671A1 (es) |
JP (1) | JP7381604B2 (es) |
KR (1) | KR20210144818A (es) |
CN (1) | CN113710694A (es) |
AU (1) | AU2020266125B2 (es) |
BR (1) | BR112021021683A2 (es) |
CA (1) | CA3138527C (es) |
IL (2) | IL292788B2 (es) |
MX (1) | MX2021010577A (es) |
SG (1) | SG11202109196XA (es) |
WO (1) | WO2020223217A1 (es) |
ZA (1) | ZA202105885B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11746334B2 (en) | 2018-11-21 | 2023-09-05 | Mayo Foundation For Medical Education And Research | Adenoviruses and methods for using adenoviruses |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6127525A (en) | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
US7332337B2 (en) | 2000-05-16 | 2008-02-19 | Galapagos Nv | Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells |
US20030219899A1 (en) | 2001-04-17 | 2003-11-27 | Nikolay Korokhov | Mosaic adenoviral vectors |
EP1611237A1 (en) | 2003-03-28 | 2006-01-04 | Merck & Co., Inc. | Adenovirus serotype 34 vectors, nucleic acids and virus produced thereby |
WO2005118825A2 (en) | 2004-05-26 | 2005-12-15 | Schering Aktiengesellschaft | Chimeric adenoviruses for use in cancer treatment |
CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
FR2874327B1 (fr) | 2004-08-19 | 2007-10-05 | Direction Et Priorites Sa Sa | Procede d'autotransfusion et dispositif d'autotransfusion a separation de phases et concentration a poches amovibles |
AP2351A (en) | 2004-10-13 | 2012-01-25 | Crucell Holland Bv | Improved adenoviral vectors and uses thereof. |
WO2011043719A1 (en) | 2009-10-05 | 2011-04-14 | Ya-Fang Mei | Replicating viral vectors for gene therapy |
US8907053B2 (en) * | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
AU2011332025B2 (en) | 2010-11-23 | 2015-06-25 | The Trustees Of The University Of Pennsylvania | Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof |
WO2012083297A2 (en) | 2010-12-17 | 2012-06-21 | Genvec, Inc. | Adenoviral vectors with modified hexon regions |
US10208304B2 (en) | 2011-04-14 | 2019-02-19 | Regents Of The University Of Minnesota | Adenovirus library and methods |
EP2807194A4 (en) * | 2012-01-27 | 2015-12-02 | Gliknik Inc | FUSION PROTEINS WITH IGG2 HINGEOMS |
WO2014047350A1 (en) | 2012-09-20 | 2014-03-27 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
EP2970510A4 (en) | 2013-03-13 | 2016-08-24 | Univ Colorado Regents | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES |
EP2940128A1 (en) | 2014-04-30 | 2015-11-04 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Adenovirus comprising an albumin-binding moiety |
PL3169341T3 (pl) | 2014-07-16 | 2019-12-31 | Transgene Sa | Wirus onkolityczny do ekspresji modulatorów punktu kontroli immunologicznej |
CA2994927A1 (en) | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity pd-1 agents and methods of use |
WO2016164428A1 (en) | 2015-04-06 | 2016-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway |
WO2017087547A1 (en) | 2015-11-17 | 2017-05-26 | Oncomed Pharmaceuticals, Inc. | Pd-l1-binding agents and uses thereof |
EP3998341A3 (en) | 2016-04-06 | 2022-08-24 | Gene Bridges GmbH | Adenoviral vectors |
WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
AU2017290828A1 (en) * | 2016-06-30 | 2019-01-24 | Virogin Biotech Canada Ltd | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
JP7260477B2 (ja) * | 2017-02-27 | 2023-04-18 | シャタック ラボ,インコーポレイテッド | Tigit及びlightベースのキメラタンパク質 |
TW202011977A (zh) | 2018-04-20 | 2020-04-01 | 貝勒醫學院 | 溶瘤病毒療法及免疫療法 |
US11746334B2 (en) | 2018-11-21 | 2023-09-05 | Mayo Foundation For Medical Education And Research | Adenoviruses and methods for using adenoviruses |
-
2020
- 2020-04-28 CA CA3138527A patent/CA3138527C/en active Active
- 2020-04-28 MX MX2021010577A patent/MX2021010577A/es unknown
- 2020-04-28 AU AU2020266125A patent/AU2020266125B2/en active Active
- 2020-04-28 CN CN202080029746.9A patent/CN113710694A/zh active Pending
- 2020-04-28 SG SG11202109196XA patent/SG11202109196XA/en unknown
- 2020-04-28 KR KR1020217034679A patent/KR20210144818A/ko not_active Application Discontinuation
- 2020-04-28 WO PCT/US2020/030240 patent/WO2020223217A1/en active Search and Examination
- 2020-04-28 BR BR112021021683A patent/BR112021021683A2/pt active Search and Examination
- 2020-04-28 JP JP2021564249A patent/JP7381604B2/ja active Active
- 2020-04-28 IL IL292788A patent/IL292788B2/en unknown
- 2020-04-28 EP EP20727450.7A patent/EP3911671A1/en active Pending
- 2020-04-28 US US16/860,637 patent/US11485767B2/en active Active
-
2021
- 2021-08-17 ZA ZA2021/05885A patent/ZA202105885B/en unknown
- 2021-10-26 IL IL287593A patent/IL287593B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US11485767B2 (en) | 2022-11-01 |
JP2022530892A (ja) | 2022-07-04 |
IL287593A (en) | 2021-12-01 |
BR112021021683A2 (pt) | 2021-12-21 |
ZA202105885B (en) | 2022-08-31 |
JP7381604B2 (ja) | 2023-11-15 |
AU2020266125B2 (en) | 2023-04-13 |
EP3911671A1 (en) | 2021-11-24 |
AU2020266125A1 (en) | 2021-09-30 |
CA3138527C (en) | 2024-03-12 |
SG11202109196XA (en) | 2021-09-29 |
KR20210144818A (ko) | 2021-11-30 |
IL292788A (en) | 2022-07-01 |
IL292788B1 (en) | 2023-08-01 |
CN113710694A (zh) | 2021-11-26 |
IL287593B (en) | 2022-06-01 |
CA3138527A1 (en) | 2020-11-05 |
IL292788B2 (en) | 2023-12-01 |
WO2020223217A1 (en) | 2020-11-05 |
US20200339654A1 (en) | 2020-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022009306A (es) | Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos. | |
MX2018016320A (es) | Moleculas de union que se unen a (pd-l1) y (lag-3). | |
MX2019009468A (es) | Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer. | |
MX2019009967A (es) | Moleculas de union biespecificas que son capaces de unirse a cd137 y a antigenos tumorales, y usos de las mismas. | |
MX2019003058A (es) | Anticuerpos monoclonales novedosos para muerte programada 1 (pd-1). | |
MX2019002474A (es) | Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres. | |
MX2021002969A (es) | Proteinas de union a nkg2d, cd16, y egfr, ccr4 o pd-l1. | |
NZ739499A (en) | Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof | |
WO2015184349A3 (en) | Multivalent ras binding compounds | |
EA201900561A1 (ru) | Конъюгаты циклодекстрин-белок-лекарственное средство | |
EA201790986A1 (ru) | Антитела к cd73 и их применения | |
TW200716743A (en) | Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics | |
SG163554A1 (en) | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) | |
MX2019009566A (es) | Proteinas de union a bcma, nkg2d y cd16. | |
PH12019500571A1 (en) | Anti-pd-1 antibodies | |
BR112022021884A2 (pt) | Proteínas que se ligam a nkg2d, cd16 e clec12a | |
MX2019009848A (es) | Proteínas que se unen a her2, nkg2d y cd16. | |
SA519401032B1 (ar) | (pd-1) جسم مضاد لموت الخلية المبرمج1 واستخدامه | |
WO2022082073A3 (en) | Compositions and methods for muc18 targeting | |
BR112022009405A2 (pt) | Composições e métodos para imunoterapia | |
MX2021010577A (es) | Compuestos de union a pd-l1 multivalentes para tratar cancer. | |
MX2020009614A (es) | Combinaciones farmaceuticas. | |
MX2021009975A (es) | Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer. | |
MX2019005212A (es) | Vacuna de adn dirigida a wt1 para terapia de combinacion. | |
MX2022001882A (es) | Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40. |